[RECORDING] HIMSS: Innovations for more equitable obesity care

GLP-1 medications have become wildly popular for weight loss and show favorable clinical results in multiple other conditions. These pioneering drugs can potentially improve the lives of many. However, the current high-cost and supply constraints raise ethical questions on who can and cannot afford them and who can and cannot access them.

The success of and access to GLP1’s may lead to the acceleration of new care models and product categories, as well as changing business models and product redesign. Ipsos’ Jackie Ilacqua joins a HIMSS panel discussion on the foresight to equitable obesity care and what's required within health system management to adapt successfully.

During this session, you will:

• Understand the disease burden in countries facing an obesity epidemic and the potential of GLP-1 development to radically improve health outcomes
• Discover GLP-1 usage trends, patient outcomes, and how today’s affordability, access, and scarcity is consequential for tomorrow
• Learn how innovations, such as telehealth, is making access to weight loss treatment accessible
• Discuss the landscape for health systems on changing patient loads and what medical device and digital health companies might need to be thinking about now to adapt 
• Walk away with resources to help your organization to be informed of the anticipated market shifts

To join us for the live session, please click here.

Missed the live session? Revisit the recording here. 

Be sure to also access this month's deep exploration of GLP-1s impact on a wide range of industries, Reshaping Society: Insights to Activate. 

Meanwhile, be sure to check out another HIMSS podcast session featuring Ipsos' Mark Polyak discussing how patients feel about the use of AI in their healthcare. 

How do consumers perceive obesity and GLP-1s? What impact are these medications having on lifestyle habits? What are the opportunities for brands? Wave 2 of the Ipsos GLP-1 Monitor, which provides an evolving multi-country perspective on this dynamic market, can answer all these questions and many more. Key insights from our study include:

• Impact of GLP-1s on consumer lifestyles
• Risks / opportunities for brands in food, beverage, retail & lifestyle sectors
• Key drivers & channels of consumer engagement
• Segmentation insights with AI-powered possibilities